These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12142384)

  • 41. Reduced stability of prostate-specific antigen after long-term storage of serum at -20 degrees C.
    Leinonen J; Stenman UH
    Tumour Biol; 2000; 21(1):46-53. PubMed ID: 10601841
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy.
    van Iersel MP; Thomas CM; Segers MF; Witjes WP; Debruyne FM; Oosterhof GO
    Br J Urol; 1996 Mar; 77(3):418-22. PubMed ID: 8814849
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
    Nurmikko P; Pettersson K; Piironen T; Hugosson J; Lilja H
    Clin Chem; 2001 Aug; 47(8):1415-23. PubMed ID: 11468231
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative study of assays for prostate-specific antigen molecular forms.
    Kuriyama M; Uno H; Ueno K; Hamamoto Y; Vihn PQ; Ban Y
    Jpn J Clin Oncol; 1999 Jun; 29(6):303-7. PubMed ID: 10418560
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared.
    Schifman RB; Ahmann FR; Elvick A; Ahmann M; Coulis K; Brawer MK
    Clin Chem; 1987 Nov; 33(11):2086-8. PubMed ID: 2445507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analytical performance of a new one-step quantitative prostate-specific antigen assay, the FREND™ PSA Plus.
    Park HI; Lee S; Kim Y; Shin DY; Lee C; Han S; Chung C; Chang JK; Seo IB
    Clin Chem Lab Med; 2014 May; 52(5):715-23. PubMed ID: 24323891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
    Catalona WJ; Richie JP; deKernion JB; Ahmann FR; Ratliff TL; Dalkin BL; Kavoussi LR; MacFarlane MT; Southwick PC
    J Urol; 1994 Dec; 152(6 Pt 1):2031-6. PubMed ID: 7525994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening.
    Link RE; Shariat SF; Nguyen CV; Farr A; Weinberg AD; Morton RA; Richardson B; Bernard D; Slawin KM
    J Urol; 2004 Jun; 171(6 Pt 1):2234-8. PubMed ID: 15126793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Free and complexed prostate-specific antigen (PSA) in the early detection of prostate cancer.
    Tello FL; Prats CH; González MD
    Clin Chem Lab Med; 2001 Feb; 39(2):116-20. PubMed ID: 11341744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disagreement between the Roche Cobas Core and Hybritech TANDEM-E PSA assays when measuring free, complexed and total serum prostate specific antigen.
    Tillyer CR; Konings M; Gobin PT; Iqbal J
    Ann Clin Biochem; 1994 Sep; 31 ( Pt 5)():501-5. PubMed ID: 7530440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.
    Blijenberg BG; Eman I; Boevé ER; Mössner E; Uhl W
    Eur J Clin Chem Clin Biochem; 1995 Jun; 33(6):383-92. PubMed ID: 7578619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time.
    Jacobsen SJ; Klee GG; Lilja H; Wright GL; Oesterling JE
    Urology; 1995 Mar; 45(3):447-53. PubMed ID: 7533456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specific antigen ratio in predicting prostatic carcinoma.
    Letran JL; Blase AB; Loberiza FR; Meyer GE; Ransom SD; Brawer MK
    J Urol; 1998 Aug; 160(2):426-9. PubMed ID: 9679891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. One-step immunostrip test for the simultaneous detection of free and total prostate specific antigen in serum.
    Fernández-Sánchez C; McNeil CJ; Rawson K; Nilsson O; Leung HY; Gnanapragasam V
    J Immunol Methods; 2005 Dec; 307(1-2):1-12. PubMed ID: 16277989
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer.
    Azzouzi AR; Larre S; Cormier L; Roupret M; Valeri A; Mangin P; Berthon P; Villette JM; Fiet J; Cussenot O
    BJU Int; 2007 Apr; 99(4):762-4. PubMed ID: 17233806
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen.
    Jacobsen SJ; Lilja H; Klee GG; Wright GL; Pettersson K; Oesterling JE
    Urology; 1994 Oct; 44(4):512-8. PubMed ID: 7524236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pre-analytical in-vitro stability of [-2]proPSA in blood and serum.
    Semjonow A; Köpke T; Eltze E; Pepping-Schefers B; Bürgel H; Darte C
    Clin Biochem; 2010 Jul; 43(10-11):926-8. PubMed ID: 20450900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA.
    Magklara A; Scorilas A; Catalona WJ; Diamandis EP
    Clin Chem; 1999 Nov; 45(11):1960-6. PubMed ID: 10545066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.